Transcriptome Profiling Reveals Distinct Phenotype of Human Bone Marrow Mesenchymal Stem Cell-derived Hepatocyte-like cells

Dongyan Shi, Jiaojiao Xin, Yingyan Lu, Wenchao Ding, Jing Jiang, Qian Zhou, Suwan Sun, Beibei Guo, Xingping Zhou, ­Jun Li­International Journal of Medical Sciences 2020 · DOI

Abstract

Human bone marrow mesenchymal stem cell-derived hepatocyte-like cells (hBMSC-HLCs) are a promising alternative to primary human hepatocytes (HHs) for treating liver disease. However, their molecular characteristics remain partially defined. This study clarifies the transcriptome of hBMSC-HLCs using mRNA sequencing, comparing them to undifferentiated hBMSCs and primary HHs. We observed significant gene expression shifts, including the upregulation of 630 genes involved in hepatic metabolism and immune response, and the downregulation of 1,082 genes associated with stemness. Five key biomarkers—TDO2, HP, SERPINA3, LBP, and SAA1—were identified and validated both in vitro and in vivo in a pig model of liver failure. These findings provide a molecular blueprint for hBMSC-HLCs, supporting their future clinical application.

Introduction

End-stage liver failure is a global health crisis with limited treatment options. While primary human hepatocytes (HHs) are the gold standard for cell therapy, their scarcity and difficulty in maintenance necessitate alternative sources. Human bone marrow mesenchymal stem cells (hBMSCs) can be differentiated into hepatocyte-like cells (HLCs), but a comprehensive molecular understanding of these cells is required to ensure safety and efficacy. This paper addresses this gap by defining the transcriptome characteristics of hBMSC-HLCs.

Methods

Researchers isolated hBMSCs from healthy volunteers and confirmed their identity through surface marker profiling and multi-lineage differentiation potential. These cells were then subjected to a 20-day hepatic induction protocol. The team employed whole-genome mRNA sequencing (mRNA-seq) to track transcriptomic changes at Day 0, Day 10, and Day 20, using primary HHs as a benchmark. Bioinformatics tools were used to identify differentially expressed genes (DEGs) and enriched biological pathways. Finally, the findings were validated in vivo by transplanting hBMSCs into a pig model of fulminant hepatic failure (FHF).

Characterization of hBMSCs and validation of hepatic differentiation. (A) Flow cytometry for MSC markers (CD29, CD90, CD34, CD45). (B) Multi-lineage differentiation potential (adipogenic and osteogenic). (C) Morphological transition during hepatic induction. (D) RT-PCR analysis of hepatic markers (ALB, AFP, TAT, TDO2) over 20 days compared to primary hepatocytes (HH).

Key Results

Morphological and Functional Transition

The differentiation process was marked by a fundamental Mesenchymal-to-Epithelial Transition (MET). Cells shifted from a spindle-like mesenchymal shape to a polygonal epithelial morphology. Functional maturation was evidenced by glycogen accumulation and the expression of classic hepatic markers such as Albumin (ALB) and α-fetoprotein (AFP).

Morphological transition of hBMSCs to HLCs. (1) Undifferentiated hBMSCs (D0); (2) Differentiating cells at Day 10; (3) Mature HLCs at Day 20 showing polygonal morphology and functional staining.

Transcriptomic Shifts and Biomarker Identification

mRNA-seq revealed 630 upregulated genes in HLCs, primarily involved in lipid metabolism and immune signaling. Conversely, 1,082 genes related to stem cell maintenance and cell cycle regulation were downregulated. A key finding was the identification of five specific genes—TDO2, HP, SERPINA3, LBP, and SAA1—that were consistently upregulated both in vitro and in the pig in vivo model. In the pig model, these genes showed a 150-fold increase in expression 7 days post-transplantation, coinciding with liver repair.

Discussion

While hBMSC-HLCs demonstrate a clear hepatic profile, they remain "immature" compared to primary hepatocytes. The transcriptome of D20 cells is significantly closer to HHs than to the original stem cells, yet a gap in full metabolic maturity persists. The identified "Big Five" biomarkers serve as critical quality control markers for future cell manufacturing and clinical monitoring.

Conclusion

hBMSC-HLCs possess a hepatic transcriptome profile and express specific genes in vitro and in vivo. The five upregulated genes identified in this study are potential biomarkers for characterizing hBMSC-HLCs in clinical applications, paving the way for improved stem cell-based therapies for liver disease.

Summary updated

Abstract

<b>Background</b>: Human bone marrow mesenchymal stem cell-derived hepatocyte-like cells (hBMSC-HLCs) are a promising alternative for primary human hepatocytes (HHs) for treating liver disease. However, the molecular characteristics of HLCs remain unclear. Here, we aimed to clarify the transcriptome characteristics of hBMSC-HLCs for future clinical application. <b>Materials and Methods</b>: hBMSCs were isolated from the bone marrow of healthy volunteers and differentiated into hepatocytes. mRNA sequencing was used in the transcriptome profiling of hBMSC-HLCs, with hBMSCs and HHs as controls. <b>Results</b>: hBMSC-HLCs exhibited a polygonal morphology, glycogen accumulation and albumin expression. A total of 630 upregulated and 1082 downregulated genes were observed in hBMSC-HLCs and HHs compared with undifferentiated hBMSCs. The upregulated genes were mainly involved in hepatic metabolism and inflammatory and immune responses. The downregulated genes were mainly associated with stem cell characteristics (multipotent differentiation, cell cycle regulation, etc.). Confirmatory qRT-PCR of 9 upregulated and 9 downregulated genes with log2 fold changes > 5 showed similar results. <i>In vivo</i> transdifferentiation of hBMSCs in pigs with fulminant hepatic failure confirmed the similarly upregulated expression of 5 hepatogenic genes (<i>TDO2, HP, SERPINA3, LBP</i> and <i>SAA1</i>), showing a 150-fold change in liver tissues at 7 days after hBMSC transplantation. These 5 genes mainly contributed to liver metabolism and inflammation. <b>Conclusion</b>: hBMSC-HLCs possess a hepatic transcriptome profile and express hepatic-specific genes <i>in vitro</i> and <i>in vivo</i>, which might be useful for future clinical applications. The five upregulated genes identified herein could be potential biomarkers for the characterization of hBMSC-HLCs.
BibTeX
@article{shi2020transcriptome,
  author = {Dongyan Shi and Jiaojiao Xin and Yingyan Lu and Wenchao Ding and Jing Jiang and Qian Zhou and Suwan Sun and Beibei Guo and Xingping Zhou and ­Jun Li­},
  title = {{Transcriptome Profiling Reveals Distinct Phenotype of Human Bone Marrow Mesenchymal Stem Cell-derived Hepatocyte-like cells}},
  journal = {International Journal of Medical Sciences},
  year = {2020},
  doi = {10.7150/ijms.36255},
}
Figure